Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study

Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study

The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis. This cross-sectional study used the Danish national registers and Danish Skin Cohort to assess the prevalence of risk factors that potentiall...

Full description

Bibliographic Details
Main Authors: Ida Vittrup, David Thein, Simon Francis Thomsen, Alexander Egeberg, Jacob P. Thyssen
Format: Article
Language:English
Published: Medical Journals Sweden 2024-01-01
Series:Acta Dermato-Venereologica
Subjects:
Atopic dermatitis
cardiovascular
JAK inhibitor
malignancy
prevalence
risk factor
Online Access:https://medicaljournalssweden.se/actadv/article/view/18638

Similar Items

Similar Items